Traditional immunotherapy has long focused on the "adaptive" immune system, specifically training T-cells to recognize and kill cancer. However, many tumors—particularly solid ones—create an immunosuppressive "sanctuary" that T-cells cannot penetrate. A growing body of research suggests that the next frontier lies in the "innate" immune system, specifically by targeting the molecular "handshakes" that prevent macrophages from engulfing and destroying tumor cells.
The Don't Eat Me Signal
Macrophages are the primary sentinels of the innate immune system, responsible for identifying and "eating" (phagocytosing) cellular debris and pathogens. To prevent these powerful cells from attacking healthy tissue, the body uses "don't-eat-me" signals—surface proteins that bind to inhibitory receptors on macrophages.
As Jiawei Zhou and colleagues explain in Tumor-Associated Macrophages: Recent Insights and Therapies, cancer cells hijack this safety mechanism. By overexpressing proteins like CD47, tumors provide a continuous inhibitory signal to macrophages, effectively wearing a "molecular camouflage" that makes them invisible to the innate immune system.
The CD47-SIRPα Axis
The most well-studied of these innate checkpoints is the interaction between CD47 on the tumor cell and SIRPα on the macrophage. Under normal conditions, this interaction protects red blood cells from being cleared prematurely. In the context of cancer, Hongyuan Pang notes in Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review) that CD47 acts as a master regulator of tumor cell fate.
When a therapeutic antibody blocks this interaction, the "don't-eat-me" signal is silenced. This allows the macrophage to recognize "eat-me" signals (like calreticulin) that are also present on the tumor surface. As Ming Yi argues in Exploiting innate immunity for cancer immunotherapy, this "innate checkpoint blockade" provides a viable pathway for clearing tumors that have become resistant to traditional T-cell therapies.
Expanding the Target Landscape
While CD47 is the pioneer, researchers are identifying a broader repertoire of inhibitory signals:
- CD24 and Siglec-10: Jun‐Li Liu and others have developed antibodies like NXA01 that target CD24, another potent "don't-eat-me" signal. In Discovery of NXA01, a novel CD24 antibody with tumor selectivity and potent anti-tumor activity, they demonstrate that targeting the specific version of CD24 found on tumors can restore phagocytosis while sparing healthy cells.
- PD-L1 on Macrophages: While PD-L1 is famous for suppressing T-cells, Han Jiang shows in PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment that PD-1 expression on macrophages themselves can hijack internal signaling (JAK2-STAT3) to suppress their anti-tumor activity.
- Cancer Stem Cell Resilience: Yan Zhang and Shuo Zhang have highlighted that cancer stem cells—the "roots" of a tumor—are particularly adept at overexpressing these signals to create an immune-privileged "sanctuary," driving recurrence even after successful chemotherapy.
Synergistic Approaches
The true power of innate checkpoint blockade appears when it is used as a "force multiplier" for other therapies.
For example, Yanni Zhang demonstrated in Combination of HER2 ADC and lemzoparlimab elicits enhanced efficacy in both HER2 high-and low-expressing breast and gastric cancers that combining an anti-CD47 antibody (lemzoparlimab) with a HER2-targeted drug conjugate significantly improved outcomes. The ADC kills some cells and releases "eat-me" signals, while the CD47 blockade ensures the macrophages are ready to finish the job.
Furthermore, Luyao Wang discusses in The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems how CRISPR can be used to knock out inhibitory receptors on macrophages or T-cells, making them permanently "blind" to the tumor's attempts at suppression.
Why It Works
The intuition behind this research direction is a shift from activation to disinhibition. Rather than just trying to "rev up" the immune system with cytokines or vaccines, these therapies remove the specific molecular brakes that tumors use to stay alive. By restoring the natural phagocytic capacity of macrophages, researchers are enabling the body’s most basic defense mechanism to recognize cancer not as a part of the self, but as a threat to be consumed.